CYAN CYANOTECH CORP
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 768408 · Fiscal year ends 03/31
Financial factors as of 2025-09-30 (2025Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.5%
TTM net income YoY67.4%
TTM EPS YoY69.9%
Revenue 3-yr CAGR-5.0%
Net income 3-yr CAGR—
Margins
Gross margin32.0%
Operating margin-4.2%
Net margin-7.0%
FCF margin-5.7%
EBITDA margin1.5%
Returns
ROE-20.0%
ROA-7.4%
ROIC (approx.)-5.3%
Asset turnover1.05x
Leverage & solvency
Liabilities / assets66.4%
Debt / equity1.04x
Current ratio1.00x
Interest coverage-1.48x
Cash quality & payout
Operating cash flow / net income0.68x
Accruals ratio-2.4%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-03-31 | FY20242024-03-31 |
|---|---|---|
| Income statement | ||
| Revenue | $24.21M | $23.07M |
| Cost of revenue | $17.34M | $17.13M |
| Gross profit | $6.88M | $5.95M |
| R&D expense | $449,000 | $689,000 |
| SG&A expense | $4.40M | $4.46M |
| Operating income | -$2.51M | -$4.59M |
| Interest expense | $687,000 | $668,000 |
| Pretax income | -$3.19M | -$5.26M |
| Income tax | $8,000 | $7,000 |
| Net income | -$3.20M | -$5.27M |
| EBITDA | -$1.03M | -$3.00M |
| EPS (basic) | -0.45 | -0.81 |
| EPS (diluted) | — | -0.81 |
| Weighted avg. shares (diluted) | — | 6,531 |
| Balance sheet | ||
| Cash & equivalents | $257,000 | $707,000 |
| Receivables | $1.95M | $2.10M |
| Inventory | $7.79M | $7.31M |
| Current assets | $10.54M | $10.59M |
| PP&E, net | $8.93M | $10.11M |
| Total assets | $23.49M | $25.11M |
| Current liabilities | $10.24M | $8.55M |
| Short-term debt | $6.65M | $5.63M |
| Long-term debt | $1.00M | $1.00M |
| Total debt | $7.65M | $6.63M |
| Total liabilities | $14.61M | $13.30M |
| Shareholders' equity | $8.88M | $11.81M |
| Net debt | $7.39M | $5.92M |
| Shares outstanding | 7.20M | 6.95M |
| Cash flow statement | ||
| Operating cash flow | -$1.19M | -$455,000 |
| Capital expenditure | $247,000 | $381,000 |
| Free cash flow | -$1.44M | -$836,000 |
| Investing cash flow | -$247,000 | -$381,000 |
| Financing cash flow | $990,000 | $569,000 |
| Depreciation & amortization | $1.48M | $1.59M |
| Stock-based compensation | $247,000 | $359,000 |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.